ZEJULA
PeakNDAORALCAPSULEPriority Review
Approved
Mar 2017
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
1
Data completeness
4/8 — Partial
Priority Review
Drug data last refreshed 8h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ZEJULA is an oral small-molecule drug approved by the FDA in March 2017, currently in peak commercial lifecycle. The indication and mechanism of action are not specified in available data, but the product is positioned as an NDA with ongoing clinical relevance.
$162MPart D
Peak11.6 years to LOEZEJULA generated $162M in Part D spending in 2023 with 10,023 claims, indicating a mature established product with stable market presence and likely mid-sized commercial team supporting promotion and patient management.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
Genome-Based Assessment of Niraparib (ZEJULA®) Efficacy in Advanced Solid TumorS With Homologous Recombination Deficiency
Started Feb 2024
33 enrolled
Efficacy
Why This Matters for Your Career
Worked on ZEJULA at GSK? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.